Skip to main content
Targeted Oncology
Genetic Alterations
Company
Management Team
Board of Directors
Scientific Advisory Board
Business Development
Careers
Contact
Pipeline
Sitravatinib (MGCD516)
KRAS G12C Inhibitor (MRTX849)
Patients
Investors
Contact
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2019
2018
2017
2016
2015
2014
2013
7/09/2019
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
7/01/2019
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
6/27/2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
6/25/2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
6/24/2019
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
5/30/2019
Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference
4/29/2019
Mirati Therapeutics Reports First Quarter 2019 Financial Results
4/01/2019
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
3/05/2019
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
2/28/2019
Mirati Therapeutics Reports Fourth Quarter Financial Results
2/19/2019
Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
2/07/2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
1/22/2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
1/16/2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
1/16/2019
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
1/15/2019
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
1/07/2019
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
1/02/2019
Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference